Novartis Omeprazole Offering, Wellpoint, Prilosec OTC Pressure PPI Prices
Novartis' entrance into the OTC loratadine market in March could set a precedent for the firm to make a similar move with the proton pump inhibitor omeprazole
More from Archive
More from Pink Sheet
• By
Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.
• By
Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.
• By
The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.